Pharmaceuticals

Renin-Angiotensin-System (RAS)-Acting Agents Market Forecast 2026: Where the Industry Is Headed

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the renin-angiotensin-system (ras)-acting agents market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Renin-Angiotensin-System (RAS)-Acting Agents Market be in 2030 compared with 2026?

The market size for renin-angiotensin-system (ras)-acting agents has experienced strong growth over recent years. This market is set to expand from $6.11 billion in 2025 to $6.44 billion in 2026, registering a compound annual growth rate (CAGR) of 5.5%. The historical growth in this sector can be attributed to elements such as a high prevalence of hypertension, the increasing aging population, the broad adoption of ACE inhibitors, a rise in cardiovascular screening, and the accessibility of affordable generic drugs.

The market size for renin-angiotensin-system (ras)-acting agents is poised for significant expansion in the coming years. It is projected to increase to $7.96 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is driven by factors such as the rising burden of chronic kidney disease, the demand for cardiometabolic medications, better treatment adherence, market expansion into developing economies, and the approval of new combination therapies. Key trends influencing this period include the increased adoption of combination antihypertensive treatments, the development of long-acting cardiovascular drugs, a heightened focus on renal protection therapies, the growth in generic RAS drug production, and a transition towards fixed-dose combinations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What Drivers Are Guiding Growth Patterns In The Renin-Angiotensin-System (RAS)-Acting Agents Market?

The rising occurrence of hypertension is anticipated to fuel the expansion of the renin-angiotensin system (RAS)-acting agents market moving forward. Hypertension, also known as high blood pressure, is a chronic health condition where the force of blood against artery walls remains excessively high. The increased prevalence of hypertension is linked to unhealthy dietary habits, particularly those high in salt and processed foods, which contribute to elevated blood pressure and impose strain on the cardiovascular system. Renin-angiotensin system (RAS)-acting agents effectively reduce hypertension by regulating blood pressure; they achieve this by inhibiting angiotensin II, a hormone responsible for constricting blood vessels and increasing fluid retention, thereby promoting vasodilation and lowering blood pressure. For example, in September 2025, the World Health Organization, a Switzerland-based intergovernmental organization, reported that an estimated 1.4 billion adults aged 30–79 globally were living with hypertension in 2024, accounting for about 33% of people in this age group. Consequently, the increasing prevalence of hypertension is a key driver for the growth of the renin-angiotensin system (RAS)-acting agents market.

How Is The Renin-Angiotensin-System (RAS)-Acting Agents Market Divided Into Segments?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

What Long-Term Trends Are Expected To Shape The Future Of The Renin-Angiotensin-System (RAS)-Acting Agents Market?

Leading enterprises within the renin-angiotensin system (RAS)-acting agents market are concentrating on creating innovative renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors, with the aim of boosting effectiveness, reducing adverse reactions, increasing patient adherence, and addressing conditions like hypertension, heart failure, and kidney ailments. An angiotensin-converting enzyme (ACE) inhibitor functions as a drug designed to decrease blood pressure by obstructing the enzyme responsible for transforming angiotensin I into angiotensin II, which is a compound known to constrict blood vessels. As an illustration, in November 2023, Proveca Ltd., a pharmaceutical firm based in the UK, secured funding from the European Commission. This grant was specifically for pediatric use marketing authorization (PUMA) of Aqumeldi (enalapril maleate) orodispersible tablets, prescribed for managing heart failure in children from birth to less than 18 years. Aqumeldi, an angiotensin-converting enzyme (ACE) inhibitor, works to treat young heart failure patients by inhibiting the angiotensin-converting enzyme (ACE), an action that stops angiotensin I from turning into angiotensin II, which in turn leads to the relaxation of blood vessels, better blood circulation, and a reduced strain on the heart.

Which Key Players Are Driving Competition In The Renin-Angiotensin-System (RAS)-Acting Agents Market?

Major companies operating in the renin-angiotensin-system (ras)-acting agents market are Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

Which Region Is Projected To Lead The Renin-Angiotensin-System (RAS)-Acting Agents Market During The Forecast Period?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (ras)-acting agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Renin-Angiotensin-System (RAS)-Acting Agents Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

Browse Through More Reports Similar to the Global Renin-Angiotensin-System (RAS)-Acting Agents Market 2026, By The Business Research Company

Angiotensin Receptor Blockers Arbs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Angina Pectoris Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Inotropic Agents Market Report 2026

https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795